Efficacy and Safety of Canagliflozin 300 mg in Overweight and Obese Type 2 Diabetes Mellitus Patients in a Real-world Setting: COLOR Study

BACKGROUND AND AIMS: To assess the efficacy and safety of canagliflozin (CANA, 300 mg/d) in overweight and obese patients with type 2 diabetes mellitus (T2DM). METHODS: In a single centre, retrospective, observational study, we included overweight or obese patients with T2DM who had HbA1c >7% and...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Indian J Endocrinol Metab
Prif Awduron: Aneja, Pankaj, Bhalla, Gaurav, Parvesh, Neeti, Aneja, Kunal, Aneja, Kashish
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Wolters Kluwer - Medknow 2019
Pynciau:
Original Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6683679/
https://ncbi.nlm.nih.gov/pubmed/31641632
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/ijem.IJEM_55_19
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg